Jazz Pharmaceuticals (JAZZ) News Today

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) shares moved higher today on a wave of FDA approvals for its oncology franchise and a favorable analyst price-target revision. Investors cheered the approval of Jazz’s Zepzelca® (lurbinectedin) plus Tecentriq® (atezolizumab) combination as the first-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC), and an upward price-target adjustment following positive Phase 4 data for its insomnia drug Xywav.

• Positive Sentiment: FDA approves Zepzelca® (lurbinectedin) plus Tecentriq® (atezolizumab) combination as first-line maintenance therapy for extensive-stage small cell lung cancer, based on Phase 3 IMforte data showing a 46% reduction in disease progression or death and a 27% reduction in mortality; the regimen is now included in NCCN guidelines. Press Release
• Positive Sentiment: Equity research analysts raise Jazz Pharmaceuticals’ price target after Xywav’s Phase 4 trial delivers strong safety and efficacy data in insomnia patients, underpinning upside potential for Jazz’s neurology portfolio. Yahoo Finance